NCT02303626View on ClinicalTrials.gov

12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Hereditary AngioedemaHAE
Interventions
DRUG

BCX4161

DRUG

Placebo

Trial Locations (40)

10029

New York

15241

Pittsburgh

17033

Hershey

20815

Chevy Chase

28277

Charlotte

35209

Birmingham

45267

Cincinnati

55446

Plymouth

63141

St Louis

Fairfax

71106

Shreveport

73131

Oklahoma City

74133

Tulsa

75231

Dallas

77555

Galveston

80907

Colorado Springs

85251

Scottsdale

91344

Granada Hills

92093

San Diego

92112

San Diego

94598

Walnut Creek

97035

Lake Oswego

98405

Tacoma

99204

Spokane

02114

Boston

Unknown

Leuven

Ottawa

Grenoble

Lille

Paris

Berlin

Frankfurt

Mörfelden-Walldorf

Budapest

Milan

Birmingham

Bristol

Cardiff

London

Manchester

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY

NCT02303626 - 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks | Biotech Hunter | Biotech Hunter